A new survey has found that most parents are accepting of the use of ketamine therapy with adolescents to treat bipolar disorder, major depressive disorder and suicidal ideation. This first-of-its-kind study assessed the attitudes of parents toward the use of ketamine as a treatment for adolescent suicidality and mood disorders. Its findings were reported in the “Journal of Child and Adolescent Psychopharmacology.”
In the report, the authors of the study stated that since parents had the capacity to make decisions for their child’s medical care, consent from parents was a crucial factor in adopting new treatments for them.
Figures from the National Institute of Mental Health show that more than 14% of adolescents in the United States suffer from mood disorders. In at least 11% of these cases, mood disorders cause acute impairment. While ketamine is yet to be approved for psychiatric use in adolescents, it has demonstrated temporary but rapid antidepressant effects when used to manage treatment-resistant mood disorders.
The authors highlighted that ketamine had become popular as a rapid-acting intervention with a lot of potential in the treatment of suicidality and treatment-resistant depression in grownups.
For their study, the researchers asked parents to complete a survey comprised of questions on their perceptions on ketamine treatments, acceptability and ketamine’s psychiatric use. The survey found that seven out of ten parents were in favor of the use of the medicine to treat the aforementioned conditions, with the authors noting that ketamine acceptability was lower for major depressive disorder and bipolar disorder, in comparison with its use in treating suicidality.
The survey also discovered that parents preferred the use of less-invasive administration routes for the drug and short-term applications, with the preferred method of drug administration being nasal spray. More than 65% of the respondents also admitted that they would be willing to try one to two ketamine doses in an emergency center for suicidal grownups.
The authors note that parents who were comfortable using other interventions for mental health in their children, those who were familiar with psychological treatments and those with a history of mental illness were more accepting of the use of ketamine as a treatment.
The main concerns parents had included the potential side effects of the drug, the potential for abuse and the lack of FDA approval for use in children outside protocols for research.
In their conclusion, the authors assert that despite growing evidence on the safety, tolerability and effectiveness of ketamine in younger populations, more research is needed.
These research findings are in a way a vote of confidence in psychedelic science and companies such as Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF), which are already offering ketamine treatments at various licensed centers.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.